Combined intraarterial 5-fluorouracil and intramuscular interferon-alpha therapy for advanced hepatocellular carcinoma

被引:0
|
作者
Ohmoto, K [1 ]
Iguchi, Y [1 ]
Mimura, N [1 ]
Tsuduki, M [1 ]
Shimabara, M [1 ]
Kuboki, M [1 ]
Yamamoto, S [1 ]
机构
[1] Kawasaki Med Sch, Dept Med, Div Hepatol, Kurashiki, Okayama 7010192, Japan
关键词
chemotherapy; 5-fluorouracil; interferon-alpha; hepatocellular; carcinoma; advanced cancer; portal tumor thrombosis;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We report the case of a 66-year-old man with hepatic cirrhosis and multiple hypervascular tumors in both lobes of the liver as well as tumor thrombi in the portal vein. After unresectable hepatocellular carcinoma was diagnosed, transcatheter arterial embolization was considered to be difficult, because he had major portal vein thrombosis. Conventional ultrasonically-guided local treatments, such as percutaneous ethanol injection therapy and radiofrequency ablation, were also of no value because the tumors were huge and multiple. Ultimately, he was treated with a combination of intraarterial 5-fluorouracil and intramuscular interferon-alpha. After treatment, the multiple tumors became non-enhancing on contrast computed tomography scans and showed a marked decrease in size. There were no serious adverse effects (such as myelosuppression or hepatotoxicity) during treatment or follow-up and the patient is doing well at present. In conclusion, a combination of intraarterial 5-fluorouracil with intramuscular interferon-alpha appears to be useful for the management of advanced hepatocellular carcinoma, especially in patients for whom more aggressive treatment is not acceptable.
引用
收藏
页码:1780 / 1782
页数:3
相关论文
共 50 条
  • [31] Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon alpha-2b for advanced hepatocellular carcinoma
    Kasai, Kazuhiro
    Sawara, Kei
    Suzuki, Kazuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [32] PROTRACTED VENOUS INFUSION 5-FLUOROURACIL AND INTERFERON-ALPHA IN ADVANCED AND REFRACTORY COLORECTAL-CANCER
    FINDLAY, M
    HILL, A
    CUNNINGHAM, D
    NORMAN, A
    NICOLSON, M
    FORD, H
    HUSBAND, J
    EVANS, C
    CARTER, R
    ANNALS OF ONCOLOGY, 1994, 5 (03) : 239 - 243
  • [33] COMBINED EFFECTS OF INTERFERON-ALPHA AND 5-FLUOROURACIL ON NORMAL LYMPHOCYTES OR COLON-CANCER CELLS
    DEFILIPPI, R
    PRETE, SP
    GIULIANI, A
    BEI, R
    YAMAUE, H
    GREINER, JW
    DEVECCHIS, L
    BONMASSAR, E
    FASEB JOURNAL, 1994, 8 (04): : A96 - A96
  • [34] Combining 5-fluorouracil with interferon-alpha in the treatment of advanced colorectal cancer: Optimism followed by disappointment
    Kjaer, M
    ANTI-CANCER DRUGS, 1996, 7 (01) : 35 - 42
  • [35] Randomized, phase II study comparing interferon combined 5-fluorouracil plus cisplatin hepatic arterial infusion with interferon combined 5-fluorouracil hepatic arterial infusion in patients with advanced hepatocellular carcinoma
    Yamashita, T.
    Arai, K.
    Sunagozaka, H.
    Ueda, T.
    Terashima, T.
    Mizukoshi, E.
    Sakai, A.
    Nakamoto, Y.
    Honda, M.
    Kaneko, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] DIFFERENT DOSE REGIMENS OF 5-FLUOROURACIL AND INTERFERON-ALPHA IN PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA
    RAGNHAMMAR, P
    BLOMGREN, H
    EDLER, D
    LUNDELL, G
    MAGNUSSON, I
    SONNENFELD, T
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (03) : 315 - 320
  • [37] PHASE-II STUDY OF CISPLATIN, 5-FLUOROURACIL AND INTERFERON-ALPHA IN RECURRENT CARCINOMA OF THE CERVIX
    LEON, CGD
    LIPPMAN, SM
    KUDELKA, AP
    EDWARDS, CL
    KAVANAGH, JJ
    INVESTIGATIONAL NEW DRUGS, 1995, 13 (01) : 73 - 76
  • [39] RATIONAL BASIS FOR THE METABOLIC MODULATION OF 5-FLUOROURACIL BY LEUCOVORIN AND INTERFERON-ALPHA
    RUSTUM, YM
    BRITISH JOURNAL OF HAEMATOLOGY, 1991, 79 : 52 - 55
  • [40] A PHASE-II TRIAL OF INTERFERON-ALPHA 2A, 5-FLUOROURACIL, AND CISPLATIN IN PATIENTS WITH ADVANCED ESOPHAGEAL-CARCINOMA
    ILSON, DH
    SIROTT, M
    SALTZ, L
    HEELAN, R
    HUANG, Y
    KERESZTES, R
    KELSEN, DP
    CANCER, 1995, 75 (09) : 2197 - 2202